Singapore, Aug 24, 2010: Australian biotechnology company, Phosphagenics, has appointed Mr Stuart James, Dr Sandra Webb and Mr Don Clarke as non-executive directors to formulate and facilitate the implementation of strategies to commercialize the company’s research and development pipeline.

The new directors have senior commercial experience and align with Phosphagenics’ transition from product development to product distribution and sales, noted the company release.

Recently, two existing directors, Prof John Mills and Mr Michael Ashton, resigned from the company's Board.

The new non-executive director, Mr Stuart James, has had an outstanding career at Mayne Pharma. Starting as Chief Operating Officer, he did oversee the restructuring of Mayne’s under-performing logistics and hospitals businesses as well as the development of its diagnostic services. He was promoted to Group Managing Director and CEO. He is currently the Chairman of Pulse Health Limited, Prime Financial Group and Progen. He also serves as non-executive Director on the Greencross Limited Board.

Dr Sandra Webb rejoins Phosphagenics, having served with the company as pharmaceutical development adviser from February 2005 to June 2006. Dr Webb is a Director of Ground Zero Pharmaceuticals. She previously served on the Boards of AusBiotech, Amrad Corporation and Quintiles.

Since 1988, Mr Don Clarke has been a partner of law firm Minter Ellison. He serves in the Melbourne Private Equity & Capital Markets Group, predominantly advising ASX-listed companies across a range of industries with emphasis on technology and manufacturing.

Mr Clarke is also the Deputy Chairman of Webjet Limited and a Director of Circadian Technologies.

“As Phosphagenics is building its product pipeline and commercial focus it is also strengthening its board. We welcome our three new Directors who are all commercially savvy and heavy-weights in their respective fields,” said, Dr Esra Ogru, CEO of Phosphagenics.